Faculty & Staff Details
|Name:||Gary W. Jean, Pharm.D., BCOP|
|Position:||Assistant Professor, Adult Medicine Division, Dallas SW|
|Bio||Dr. Jean is an Assistant Professor of Pharmacy Practice at Texas Tech University Health Sciences Center School of Pharmacy and a Clinical Pharmacist in Hematology/Oncology at UT Southwestern Medical Center in Dallas. He received his Doctor of Pharmacy from Texas Tech University Health Sciences Center School of Pharmacy in 2008. Dr. Jean completed his Pharmacy Practice Residency at the VA Medical Center in Dallas, as well as his specialty residency in Hematology/Oncology in conjunction with Texas Tech University Health Sciences Center School of Pharmacy. His practice interests include medical oncology, malignant hematology, supportive care, and palliative care. Research interests include optimizing pharmacist role in supportive care and palliative care, and pharmacoeconomics. Before returning to Texas Tech University Health Sciences Center School of Pharmacy, Dr. Jean practiced as a clinical pharmacist on the medical oncology service at LSU Health Sciences Center in Shreveport, LA.
Dr. Jean is responsible for didactic lectures and clerkship teaching of Pharm.D. students and supervises their activities at UT Southwestern Medical Center in Dallas.
Dr. Jean received his Doctor of Pharmacy from Texas Tech University Health Sciences Center School of Pharmacy in 2008.
Dr. Jean completed a 1 year Pharmacy Practice Residency and a 1 year Hematology/Oncology Specialty Residency at the Dallas VA Medical Center.
July 2008 Texas Registered Pharmacist - #46250
June 2010 Louisiana Register Pharmacist - #PST.19082
October 2011 Board Certified Oncology Pharmacist
Shah SR, Jean GW, Keisner SV, Gressett Ussery SM, Dowell JE. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer. 2012; 20:87-93
Keisner SV, Shah SR, Jean GW, Ussery SM, Dowell JE. Retrospective analysis of consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer. Ann Pharmacother. 2010; 44: 1538-44
Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008;28:742-54.
Peer Reviewed Abstracts:
Volodin L, Bhanderi V, Shahan J, Leary C, Jean G, Comeau J, Cotelingham J, Hildebrandt GC. Romiplostim for the treatment of amegakaryocytic thrombocytopenia secondary to remission-inducing immunomodulation in a patient with relapsing acute lymphoblastic leukemia after allogeneic HSCT. ASCO Meeting Abstracts 2011:6609
Jean GW, Shah SR, Keisner SV, et al. Response to ketoconazole after failure of docetaxel in patients with advanced androgen independent prostate cancer. J Clin Oncol 28, 2010 (suppl; abstr e 15052)
Shah SR, Jean GW, Keisner SV, et al. An incidence of renal failure in patients receiving renally adjusted zolderonic acid. J Clin Oncol 28, 2010 (suppl; abstr e 19581)
Keisner SV, Shah SR, Jean GW, et al. A retrospective analysis of the consequences0 of acid suppressive therapy (AST) on ketoconazole (K) efficacy in advanced androgen-independent prostate cancer (AIPC). J Clin Oncol 28, 2010 (suppl; abstr e 15114)